Reuters logo
BRIEF-Sucampo Pharmaceuticals announces FDA acceptance of sNDA for AMITIZA
2017年9月28日 / 晚上9点40分 / 3 个月前

BRIEF-Sucampo Pharmaceuticals announces FDA acceptance of sNDA for AMITIZA

Sept 28 (Reuters) - Sucampo Pharmaceuticals Inc

* Sucampo Pharmaceuticals announces FDA acceptance of sNDA for amitiza in children with pediatric functional constipation, with priority review designation

* Sucampo Pharmaceuticals Inc - ‍FDA has assigned a user fee goal date of January 28, 2018.​

* Sucampo Pharmaceuticals Inc - ‍filing has received priority review designation from FDA​ Source text for Eikon: Further company coverage:

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below